Boston Scientific (BSX) Liabilities and Shareholders Equity (2009 - 2026)

Boston Scientific has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $45.2 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $45.2 billion, up 8.8% year-over-year; the trailing twelve-month figure through Jun 2026 was $175.9 billion (up 10.54% YoY), and the FY2025 annual result was $43.7 billion, up 10.86% from the prior year.
• Liabilities and Shareholders Equity advanced to $45.2 billion in Q2 2026, from $44.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $45.2 billion in Q2 2026 and troughed at $31.9 billion in Q3 2022.
• A 5-year average of $37.4 billion and a median of $36.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity advanced 0.22%; it then grew 12.16% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $32.5 billion in 2022, then advanced by 8.21% to $35.1 billion in 2023, then increased by 12.12% to $39.4 billion in 2024, then increased by 10.86% to $43.7 billion in 2025, then climbed by 3.53% to $45.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $45.2 billion in Q2 2026, $44.4 billion in Q1 2026, and $43.7 billion in Q4 2025.